Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission

Inclusion Criteria: * Patients with de novo AML (French-American-British \[FAB\] MO-M2, M4-M7) or secondary AML who achieve CR1 after induction chemotherapy and one or two cycles of consolidation chemotherapy * Transplant conditioning must occur within 6 months of diagnosis * Patient enrollment must be approved by the Fred Hutchinson Cancer Research Center (FHCRC) principal investigator (PI) or the PI's designee * DONOR: Related donor who is genotypically or phenotypically identical * DONOR: Age \>= 12 years * DONOR: Donor must consent to filgrastim (G-CSF) administration and leukapheresis * DONOR: Donor must have adequate veins for leukapheresis or agree to placement of central venous catheter (femoral, subclavian) Exclusion Criteria: * AML FAB M3 * AML involvement of the central nervous system (CNS) as defined by a positive cytospin of cerebral spinal fluid at the time of enrollment * Presence of circulating leukemic blasts (in the peripheral blood) detected by standard pathology * Human immunodeficiency virus (HIV) seropositivity * Fungal infections with radiographic progression after receipt of amphotericin B or active triazole for greater than one month * Diffusion capacity of carbon monoxide (DLCO) corrected \< 40% * Total lung capacity (TLC) \< 40% * Forced expiratory volume in one second (FEV1) \< 40% or requiring supplementary oxygen * The FHCRC principal investigator of the study must approve enrollment of all patients with pulmonary nodules * Cardiac ejection fr…